Head-to-head evidence
insulin icodec vs LY900014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin icodec · Awiqli
Marketed by Novo Nordisk
NCT04760626 · Phase 3 · completed
The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.
Next expected readout: October 2027 · NCT07747402 (registry estimate)
LY900014 · Lyumjev
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin icodec's landscape · LY900014's landscape